Found 6006 clinical trials
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy
Participants will be people with PCNSL who continue to have cell free tumor DNA (cfDNA) in their CSF despite completion of their first treatment (first-line treatment).
- 0 views
- 05 Aug, 2020
Video-assisted Thoracoscopic Thymectomy Versus Subxiphoid Procedure
Surgerys used in thymectomy for myasthenia gravis and anterior mediastinal tumours have become much less invasive in recent years. In our study, the surgical technique which resected the thymus below the xiphoid process and the technique which was regarded as conventional video- assisted thoracoscopic surgery (VATS) thymectomy was compared.
- 0 views
- 16 Feb, 2024
- 1 location
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
Approximately 100 adult participants with locally advanced, recurrent, or metastatic solid tumors will be enrolled.
- 0 views
- 16 Feb, 2024
- 2 locations
Vacuum Assisted Biopsy Immediately Before Surgery as an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer
Neoadjuvant chemotherapy (NAC) is common practice in the primary treatment of breast cancer, leading to a complete pathologic remission (pCR) of the tumor in more than 50% in aggressive tumor types. As NAC induces different response patterns, radiologic imaging is not sufficiently accurate in predicting residual disease.
- 0 views
- 16 Feb, 2024
- 16 locations
Safety Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies
A 3-part (dose-escalation, dose-expansion and cohort-expansion) phase I clinical study of JS004 in subjects with advanced solid malignancies in China for the first time, to evaluate the safety, tolerability, PK, immunogenicity, antitumor activity and biomarkers of JS004, define the MTD and RP2D.
- 0 views
- 16 Feb, 2024
- 1 location
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.
Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac …
- 0 views
- 16 Feb, 2024
- 1 location
Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body
The drug blocks the action of the NTRK gene fusion and prevents the activation of certain proteins (TRK fusion proteins), which can cause cancer cells to multiply and form a tumor. Researchers also want to find out if the participants have any medical problems during this study.
- 0 views
- 16 Feb, 2024
- 1 location
A Randomized Multi-institutional Study of Sodium Thiosulfate as Auditory Protection for Children With Hepatoblastoma
A Phase 3 multi-institutional study for treatment of children with newly diagnosed hepatoblastoma using a modified Paediatric Hepatic International Tumour Trial (PHITT) strategy incorporating a randomized assessment of sodium thiosulfate as auditory protection for children with localized disease, and response adapted therapy for patients with metastatic disease
- 0 views
- 16 Feb, 2024
- 1 location
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
The investigators hypothesize that intermittent first-line Panitumumab plus FOLFIRI is effective as the same regimen given continuously, in unresectable metastatic RAS and BRAF wild type colorectal cancer patients. Correlative studies on tumor and blood samples could identify potential biomarkers of efficacy and help defining personalized treatment strategy.
- 0 views
- 16 Feb, 2024
- 1 location
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
T lymphocytes can kill tumor cells but there normally are not enough of them to kill all the tumor cells. Some researchers have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the person.
- 0 views
- 16 Feb, 2024
- 1 location